Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065609 · ClinicalTrials.gov registry record · Early Phase 1
89ZrTrastuzumab Breast Imaging With Positron Emission Tomography
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
NCT02065609: Completed Early Phase 1 study, sponsored by Washington University School of Medicine.
NCT02065609 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 52 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02065609, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
Primary Outcome
Subjects medical record was followed for 30 days following 89Zr-Trastuzumab Administration for AE Assessment with AE being defined as Any unfavorable medical occurrence in a human subject who receives 89Zr-Trastuzumab and PET/CT imaging, including any abnormal sign, symptom, or disease. The event does not necessarily have to be causally related to injection of 89Zr-Trastuzumab or PET/CT imaging to qualify as an adverse event, just temporally related.
Interventions
- DRUG 89Zr-Trastuzumab Human Dosimetry and Safety
- DRUG HER2 Positive Lesion Detection and Safety
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-02-13 |
| Phase | Early Phase 1 |
What the finished NCT02065609 record still lists
NCT02065609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which 89Zr-Trastuzumab Human Dosimetry and Safety is the first listed.
NCT02065609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02065609 about?
NCT02065609 is a clinical study titled "89ZrTrastuzumab Breast Imaging With Positron Emission Tomography". The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
What is the current status of trial NCT02065609?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2014-02. Estimated completion is 2018-02-13.
What interventions are being tested in trial NCT02065609?
The interventions under investigation include: 89Zr-Trastuzumab Human Dosimetry and Safety (DRUG), HER2 Positive Lesion Detection and Safety (DRUG).
Who is sponsoring clinical trial NCT02065609?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02065609's enrollment target sits among peer trials
52 477th of 2000 higher than 1,516 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia